Even in healthcare systems with universal free access, like the UK's NHS, the actual uptake of immunotherapy for metastatic kidney cancer is only about 60%. This real-world gap strengthens the argument for adjuvant therapy, as it ensures high-risk patients receive potentially life-saving treatment they might otherwise miss upon relapse.

The standard of care for non-muscle invasive bladder cancer, BCG, has been on backorder for nearly a decade. This creates a significant market opening for new treatments driven not just by clinical need for better efficacy, but by a fundamental failure in supply chain and access for the incumbent therapy.

NGene's product design equally weighs efficacy, tolerability, and ease of use. Recognizing that most patients are treated in community settings, the therapy's simple preparation and administration are tailored to fit seamlessly into a community urologist's practice dynamics, a critical factor for adoption that goes beyond clinical data.

Circulating tumor DNA (ctDNA) is a powerful biomarker for identifying high-risk bladder cancer patients. However, its imperfection presents a new clinical dilemma: with a ~12% relapse rate even in ctDNA-negative patients, clinicians must decide whether to withhold adjuvant therapy and accept that risk, or overtreat the 88% who are likely cured.

Upcoming trials like RETAIN and IMVigor011 are using circulating tumor DNA (ctDNA) to guide complex treatment choices in muscle-invasive bladder cancer. This biomarker-driven approach aims to personalize therapy, potentially enabling bladder preservation for some patients and identifying others who need additional adjuvant treatment.

The POTOMAC trial's success adding durvalumab to BCG for non-muscle invasive bladder cancer introduces a major logistical hurdle. Urologists, who typically manage these patients, often lack the expertise to handle systemic immunotherapy side effects, creating uncertainty about which specialty will administer this new standard of care.

Despite strong efficacy data, the drug DV-Toripalimab scored lower than a competitor (2.5 vs 3.0). Experts attribute this confidence gap to its Phase 3 trial being conducted only in China, which raises generalizability concerns and reflects a lack of hands-on experience for Western physicians.

While promising, current ctDNA technology is not robust enough to justify stopping effective neoadjuvant systemic therapy in bladder cancer, even if a patient becomes ctDNA negative. Experts argue against using it to de-escalate treatment outside of a clinical trial due to the risk of undertreating a lethal disease.

A key lesson in bladder cancer is that patient attrition is rapid between lines of therapy; many who relapse from localized disease never receive effective later-line treatments. This reality provides a strong rationale for moving the most effective therapies, like EV-pembrolizumab, to earlier settings to maximize the number of patients who can benefit.